Breast tumor characteristics as predictors of mammographic detection: Comparison of interval- and screen-detected cancers

Journal of the National Cancer Institute

Volumn 91, Issue 23, 1999, Pages 2020-2028

  Porter, Peggy L ^a,b   El Bastawissi, Amira Y ^c   Mandelson, Margaret T ^b   Lin, Ming Gang ^c   Khalid, Najma ^c   Watney, Elizabeth A ^c   Cousens, Laura ^c   White, Donna ^c   Taplin, Stephen ^b   White, Emily ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Group Health Cooperative ^*

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER SCREENING; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; ONCOGENE C ERB; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

EID: 0033485819     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.23.2020     Document Type: Article

References (40)

1. Holland R, Mravunac M, Hendriks JH, Bekker BV. So-called interval cancers of the breast. Pathologic and radiologic analysis of sixty-four cases. Cancer 1982;49:2527-33.
2. Martin JE, Moskowitz M, Milbrath JR. Breast cancer missed by mammography. AJR Am J Roentgenol 1979;132:737-9.
3. Frisell J, Eklund G. Hellstrom L. Somell A. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Res Treat 1987;9:219-25.
4. Heuser L, Spratt JS Jr, Polk HC Jr, Buchanan J. Relation between mammary cancer growth kinetics and the intervals between screenings. Cancer 1979;43:857-6.
5. Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 1992;84: 781-5.
6. Adler OB, Engel A. Invasive lobular carcinoma. Mammographic pattern. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1990; 152:460-2.
7. Holland R, Hendriks JH, Mravunac M. Mammographically occult breast cancer. A pathologic and radiologic study. Cancer 1983;52: 1810-9.
8. van Gils CH, Otten JD, Verbeek AL, Hendriks JH. Mammographic breast density and risk of breast cancer: masking bias or causality? Eur J Epidemiol 1998;14:315-20.
9. von Fournier D, Weber E. Hoeffner W, Kubli F, Barth V. Growth rate of 147 mammary carcinomas. Cancer 1980;45:2198-207.
10. DeGroote R, Rush BF Jr, Milazzo J, Warden MJ, Rocko JM. Interval cancer: a more aggressive subset of breast neoplasias. Surgery 1983; 94:543-7.
11. Heuser LS, Spratt JS, Kuhns JG, Chang AF, Polk HC Jr, Buchanan JB. The association of pathologic and mammographic characteristics of primary human breast cancers with "slow" and "fast" growth rates and with axillary lymph node metastases. Cancer 1984;53:96-8.
12. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ. Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 1996;78:1220-8.
13. Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H. Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 1997;75: 762-6.
14. Ikeda D, Andersson I, Wattsgard C, Janzon L, Linell F. Interval cancers in the Malmo Mammographic Screening Trial: radiographic appearance and prognostic considerations. AJR Am J Roentgenol 1992;159:287-94.
15. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S. Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 1992;24: 11-6.
16. Hatschek T, Fagerberg G, Stal O, Sullivan S, Carstensen J, Grontoft O, et al. Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer 1090;64:1074-81.
17. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81: 1879-86.
18. Carter AP, Thompson RS, Bourdeau RV, Andenes J, Mustin H, Straley H. A clinically effective breast cancer screening program can be cost-effective, too. Prev Med 1987;16:19-34.
19. Taplin SH, Thompson RS, Schnitzer F, Anderman C, Immanuel V. Revisions in the risk-based Breast Cancer Screening Program at Group Health Cooperative [published erratum appears in Cancer 1991;67:2400]. Cancer 1990;66:812-8.
20. American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). 3rd ed. Reston (VA): American College of Radiolgy; 1993.
21. American Joint Committee on Cancer. Manual for staging of cancer. 3rd ed. Philadelphia (PA): Lippincott; 1988.
22. Bloom H, Richardson W. Histologic grading and prognosis in breast cancer. Br J Cancer 1957;11:359-77.
23. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;15: 2612-24.
24. Nourse J, Firpo E, Flanagan WM, Coats S, Polyak C, Lee MH, et al. Interleukin-2-mediated elimination of p27Kipl cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 1994;372:570-3.
25. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993;59:1908-12.
26. Gerdes J, Becker MH, Key G, Cattoretti G. Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues [letter]. J Pathol 1992;68:85-6.
27. Hsu S, Raine L, Fanger H. Use of biotin-avidin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody techniques. Am J Clin Pathol 1981;75:816-21.
28. Hsu SM, Soban E. Color modification of diaminobenzidine (DAB) precipitation by metallic ions and its application for double immunohistochemistry. J Histochem Cytochem 1982;30:1079-82.
29. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, et al. Expression of cell-cycle regulators p27Kipl and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat Med 1997;3:222-5.
30. von Fournier D, Abel U, Spratt JA, Spratt JS, Anton H. Growth rate of breast cancer, implication for early detection and therapeutic effects. Geburtshilfe Frauenheilkde 1994;54: 286-90.
31. Hakama M, Holli K, Isola J, Kallioniemi OP, Karkkainen A, Visakorpi T, et al. Aggressiveness of screen-detected breast cancers. Lancet 1995;345:221-4.
32. McGuire WL. Prognostic factors for recurrence and survival in human breast cancer. Breast Cancer Res Treat 1987;10:5-9.
33. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
34. Spratt JA, von Fournier D, Spratt JS, Weber EE. Mammographic assessment of human breast cancer growth and duration. Cancer 1993;71:2020-6.
35. Moss SM, Coleman DA, Ellman R, Chamberlain J, Forrest AP, Kirkpatrick AE, et al. Interval cancers and sensitivity in the screening centres of the UK trial of early detection of breast cancer. Eur J Cancer 1993;29A:255-8.
36. Burhenne HJ, Burhenne LW, Goldberg F, Hislop TG, Worth AJ, Rebbeck PM, et al. Interval breast cancers in the screening mammography program of British Columbia: analysis and classification. AJR Am J Roentenol 1994;162: 1067-71.
37. Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994;16:35-42.
38. Peer PG, van Dijck JA, Hendriks JH, Holland R, Verbeek AL. Age-dependent growth rate of primary breast cancer. Cancer 1993;71: 3547-51.
39. Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr 1997;22:79-86.
40. Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996;88:643-9.